Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 31;2(10):841-2.
doi: 10.18632/oncoscience.226. eCollection 2015.

EMT in immuno-resistance

Stéphane Terry  1 , Salem Chouaib  1
Affiliations

EMT in immuno-resistance

Stéphane Terry et al. Oncoscience. .
No abstract available

Keywords: CSC; EMT; cytotoxic T lymphocytes; immune resistance; tumor plasticity.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

No potential conflicts of interest were disclosed.

Figures

Figure 1
Figure 1. Schematic model for the emergence of EMTed tumor variants resistant to cytotoxic T lymphocytes
EMT may be driven by a conjunction of environmental changes, combined with evolutionary pressures and oncogenic events emerging during tumor development. EMT may be partial or reversible with cells transitioning from an epithelial to mesenchymal state, either partially or fully, and then reverting back to a more epithelial state (MET). This reflects the plasticity of cells undergoing EMT or MET. As we now understand it, cancer cells that have acquired a more mesenchymal phenotype also show reduced susceptibility to CTL-mediated killing as well as a gain of stem-like properties. Whether these resistant variants may cooperate to escape immunosurveillance is currently unknown. Likewise, it remains unclear to what extent distinct or variable mesenchymal-like states may impact differently on susceptibility to CTL. Of note, there may be multiple rounds of EMT and MET in the life of a cancer cell (primary versus metastatic sites) potentially controlled by signals produced from different microenvironments.
See this image and copyright information in PMC

References

    1. Thiery JP, et al. Cell. 2009;139:871–890. - PubMed
    1. Pattabiraman DR, Weinberg RA. Nat Rev Drug Discov. 2014;13:497–512. - PMC - PubMed
    1. Akalay I, et al. Cancer Res. 2013;73:2418–2427. - PubMed
    1. Akalay I, et al. Oncogene. 2015;34:2261–2271. - PubMed
    1. Kudo-Saito C, et al. Cancer Cell. 2009;15:195–206. - PubMed

LinkOut - more resources